Skip to main content
. 2021 Sep 17;5(18):3528–3539. doi: 10.1182/bloodadvances.2021004865

Figure 3.

Figure 3.

Outcomes after allo-HCT according to disease status at allo-HCT. (A) NRM. (B) Relapse/progression. (C) PFS. (D) OS. Histology at relapse (CLL/SLL vs DLBCL-RS) was not available; therefore, any relapse was considered a relapse and PFS event.